Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.

Autor:	Havranek O; Department of Lymphoma and Myeloma., Xu J; Department of Lymphoma and Myeloma., Köhrer S; Department of Leukemia., Wang Z; Department of Lymphoma and Myeloma., Becker L; Department of Lymphoma and Myeloma., Comer JM; Department of Lymphoma and Myeloma., Henderson J; Department of Lymphoma and Myeloma., Ma W; Department of Lymphoma and Myeloma., Man Chun Ma J; Department of Lymphoma and Myeloma., Westin JR; Department of Lymphoma and Myeloma., Ghosh D; Department of Lymphoma and Myeloma., Shinners N; Department of Lymphoma and Myeloma., Sun L; Department of Lymphoma and Myeloma., Yi AF; Department of Lymphoma and Myeloma., Karri AR; Department of Lymphoma and Myeloma., Burger JA; Department of Leukemia., Zal T; Department of Immunology, and., Davis RE; Department of Lymphoma and Myeloma.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2017 Aug 24; Vol. 130 (8), pp. 995-1006. Date of Electronic Publication: 2017 Jun 23.
DOI:	10.1182/blood-2016-10-747303
Abstrakt:	We used clustered regularly interspaced short palindromic repeats/Cas9-mediated genomic modification to investigate B-cell receptor (BCR) signaling in cell lines of diffuse large B-cell lymphoma (DLBCL). Three manipulations that altered BCR genes without affecting surface BCR levels showed that BCR signaling differs between the germinal center B-cell (GCB) subtype, which is insensitive to Bruton tyrosine kinase inhibition by ibrutinib, and the activated B-cell (ABC) subtype. Replacing antigen-binding BCR regions had no effect on BCR signaling in GCB-DLBCL lines, reflecting this subtype's exclusive use of tonic BCR signaling. Conversely, Y188F mutation in the immunoreceptor tyrosine-based activation motif of CD79A inhibited tonic BCR signaling in GCB-DLBCL lines but did not affect their calcium flux after BCR cross-linking or the proliferation of otherwise-unmodified ABC-DLBCL lines. CD79A-GFP fusion showed BCR clustering or diffuse distribution, respectively, in lines of ABC and GCB subtypes. Tonic BCR signaling acts principally to activate AKT, and forced activation of AKT rescued GCB-DLBCL lines from knockout (KO) of the BCR or 2 mediators of tonic BCR signaling, SYK and CD19. The magnitude and importance of tonic BCR signaling to proliferation and size of GCB-DLBCL lines, shown by the effect of BCR KO, was highly variable; in contrast, pan-AKT KO was uniformly toxic. This discrepancy was explained by finding that BCR KO-induced changes in AKT activity (measured by gene expression, CXCR4 level, and a fluorescent reporter) correlated with changes in proliferation and with baseline BCR surface density. PTEN protein expression and BCR surface density may influence clinical response to therapeutic inhibition of tonic BCR signaling in DLBCL. (© 2017 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu